Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 28, 2012

View Archived Issues

Resiniferatoxin improves urodynamic parameters in patients with overactive bladder

Solabegron demonstrates efficacy in phase II study

Long-term and post hoc phase III data presented on mirabegron

Ventana Medical Systems image analysis application cleared for use in U.S.

MorphoSys announces signing of protein engineering agreement

Affymax to receive milestone payment related to peginesatide

Watson Pharmaceuticals receives FDA complete response letter for vaginal gel

Ready-to-use oral therapy approved in China for oral mucositis in patients with cancer

Stem CentRx reports new APCDD1-binding antibodies

Bayer Schering Pharma patents novel potential anticancer agents

Novel antibacterials announced by Ranbaxy Laboratories

New aryl hydrocarbon receptor modulators developed in U.S.

New recombinant bacteria designed in Canada

Novartis identifies novel acetyl-CoA carboxylase 2 inhibitors

Study shows predictive value of PET/CT findings in retinoblastoma

Merck & Co. licenses Protein Sciences technology for vaccine research

Biodesix enters new collaboration

Advaxis reports data from first cohort in phase II ADXS-HPV trial

FDA grants priority review to Xarelto sNDA

Tranzyme Pharma and Norgine give update on ULISES 008 study

Two phase III cariprazine studies in schizophrenia meet primary endpoint

FDA grants fast track status to epicutaneous skin patch for peanut allergy

Apeiron begins study in prevention of radiation dermatitis

FDA grants Repros meeting to discuss Androxal development

Adocia's fast-acting human insulin comparable to NovoLog in phase IIa trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...